334 related articles for article (PubMed ID: 30232757)
21. Gut microbiota: A player in aging and a target for anti-aging intervention.
Vaiserman AM; Koliada AK; Marotta F
Ageing Res Rev; 2017 May; 35():36-45. PubMed ID: 28109835
[TBL] [Abstract][Full Text] [Related]
22. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity.
Tai N; Wong FS; Wen L
Rev Endocr Metab Disord; 2015 Mar; 16(1):55-65. PubMed ID: 25619480
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases.
Konturek PC; Haziri D; Brzozowski T; Hess T; Heyman S; Kwiecien S; Konturek SJ; Koziel J
J Physiol Pharmacol; 2015 Aug; 66(4):483-91. PubMed ID: 26348073
[TBL] [Abstract][Full Text] [Related]
24. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?
Sircana A; Framarin L; Leone N; Berrutti M; Castellino F; Parente R; De Michieli F; Paschetta E; Musso G
Curr Diab Rep; 2018 Sep; 18(10):98. PubMed ID: 30215149
[TBL] [Abstract][Full Text] [Related]
25. Diet, gut microbiota and cognition.
Proctor C; Thiennimitr P; Chattipakorn N; Chattipakorn SC
Metab Brain Dis; 2017 Feb; 32(1):1-17. PubMed ID: 27709426
[TBL] [Abstract][Full Text] [Related]
26. The role of Gut Microbiota in the development of obesity and Diabetes.
Baothman OA; Zamzami MA; Taher I; Abubaker J; Abu-Farha M
Lipids Health Dis; 2016 Jun; 15():108. PubMed ID: 27317359
[TBL] [Abstract][Full Text] [Related]
27. The contribution of microbial biotechnology to sustainable development goals: microbiome therapies.
O'Toole PW; Paoli M
Microb Biotechnol; 2017 Sep; 10(5):1066-1069. PubMed ID: 28696041
[TBL] [Abstract][Full Text] [Related]
28. Role of gut microbiota in obesity, type 2 diabetes and Alzheimer's disease.
Naseer MI; Bibi F; Alqahtani MH; Chaudhary AG; Azhar EI; Kamal MA; Yasir M
CNS Neurol Disord Drug Targets; 2014 Mar; 13(2):305-11. PubMed ID: 24059313
[TBL] [Abstract][Full Text] [Related]
29. Diet and the Microbiome.
Murtaza N; Ó Cuív P; Morrison M
Gastroenterol Clin North Am; 2017 Mar; 46(1):49-60. PubMed ID: 28164852
[TBL] [Abstract][Full Text] [Related]
30. The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity.
Kasselman LJ; Vernice NA; DeLeon J; Reiss AB
Atherosclerosis; 2018 Apr; 271():203-213. PubMed ID: 29524863
[TBL] [Abstract][Full Text] [Related]
31. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.
Distrutti E; Monaldi L; Ricci P; Fiorucci S
World J Gastroenterol; 2016 Feb; 22(7):2219-41. PubMed ID: 26900286
[TBL] [Abstract][Full Text] [Related]
32. Gut microbiota as potential orchestrators of irritable bowel syndrome.
Bennet SM; Ohman L; Simren M
Gut Liver; 2015 May; 9(3):318-31. PubMed ID: 25918261
[TBL] [Abstract][Full Text] [Related]
33. [Host-microbiota crosstalk and cardiovascular diseases].
Amar J
Presse Med; 2018 Sep; 47(9):775-779. PubMed ID: 29909161
[TBL] [Abstract][Full Text] [Related]
34. Interindividual variability in gut microbiota and host response to dietary interventions.
Healey GR; Murphy R; Brough L; Butts CA; Coad J
Nutr Rev; 2017 Dec; 75(12):1059-1080. PubMed ID: 29190368
[TBL] [Abstract][Full Text] [Related]
35. Gut Microbiota and Energy Expenditure in Health and Obesity.
Bakker GJ; Zhao J; Herrema H; Nieuwdorp M
J Clin Gastroenterol; 2015; 49 Suppl 1():S13-9. PubMed ID: 26447957
[TBL] [Abstract][Full Text] [Related]
36. Irritable bowel syndrome: a gut microbiota-related disorder?
Bhattarai Y; Muniz Pedrogo DA; Kashyap PC
Am J Physiol Gastrointest Liver Physiol; 2017 Jan; 312(1):G52-G62. PubMed ID: 27881403
[TBL] [Abstract][Full Text] [Related]
37. Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction.
Hoel H; Hove-Skovsgaard M; Hov JR; Gaardbo JC; Holm K; Kummen M; Rudi K; Nwosu F; Valeur J; Gelpi M; Seljeflot I; Ueland PM; Gerstoft J; Ullum H; Aukrust P; Nielsen SD; Trøseid M
Sci Rep; 2018 Apr; 8(1):6725. PubMed ID: 29712976
[TBL] [Abstract][Full Text] [Related]
38. The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.
Sanduzzi Zamparelli M; Compare D; Coccoli P; Rocco A; Nardone OM; Marrone G; Gasbarrini A; Grieco A; Nardone G; Miele L
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483246
[TBL] [Abstract][Full Text] [Related]
39. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders.
Rajani C; Jia W
Clin Sci (Lond); 2018 Apr; 132(7):791-811. PubMed ID: 29661926
[TBL] [Abstract][Full Text] [Related]
40. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice.
De Palma G; Lynch MD; Lu J; Dang VT; Deng Y; Jury J; Umeh G; Miranda PM; Pigrau Pastor M; Sidani S; Pinto-Sanchez MI; Philip V; McLean PG; Hagelsieb MG; Surette MG; Bergonzelli GE; Verdu EF; Britz-McKibbin P; Neufeld JD; Collins SM; Bercik P
Sci Transl Med; 2017 Mar; 9(379):. PubMed ID: 28251905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
